Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)
Inhibrx Biosciences (INBX) reported Cash from Investing Activities of -$7000.0 for Q3 2025, up 97.17% year-over-year from -$3550.3 in Q3 2024, and up 66.67% quarter-over-quarter from -$21000.0 in Q1 2025.
Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Cash from Investing Activities data on file, last reported at -$7000.0 in Q3 2025.
- Cash from Investing Activities for Q3 2025 came in at -$7000.0, up 97.17% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28000.0 (up 98.92% YoY), and the FY2025 annual result was -$28000.0, up 98.92% from the prior year.
- Cash from Investing Activities climbed to -$7000.0 in Q3 2025 per INBX's latest filing, from -$21000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$7000.0 in Q3 2025 and troughed at -$3.4 million in Q4 2023.
- A 3-year average of -$859750.0 and a median of -$529000.0 in 2023 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 99.54% in 2024 and fell as far as 69.54% in 2024.
- A 3-year view of Cash from Investing Activities shows it stood at -$3.4 million in 2023, then soared by 99.54% to -$16000.0 in 2024, then soared by 56.25% to -$7000.0 in 2025.
- Business Quant data shows INBX's Cash from Investing Activities at -$7000.0 in Q3 2025, -$21000.0 in Q1 2025, and -$16000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Jun 30, 2024 | -1.22 Mn |
| Jun 30, 2024 | -1.22 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -811,000.00 |
| Sep 30, 2023 | -811,000.00 |